(Q60673301)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Virginia Kwitkowski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Lori Minasian

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Nana Tchabo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ahalya Premkumar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Richard Chang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Edwin M Posadas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Herbert L Kotz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Mahrukh M Hussain

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Seth M Steinberg

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Elise C Kohn

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

309-317

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Systemic therapy for ovarian cancer: current status and new treatments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Cell signalling: growth factors and tyrosine kinase receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Killing time for cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Platelet-derived growth factor receptors: a therapeutic target in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Pharmacology of imatinib (STI571).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Gastrointestinal stromal tumor workshop.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Oncogenic derivatives of platelet-derived growth factor receptors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Hepatocyte growth factor and stem cell factor involvement in paracrine interplays of theca and granulosa cells in the human ovary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Expression of c-kit and kit ligand proteins in normal human tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Imatinib mesylate and its potential implications for gynecologic cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Laser capture microdissection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Expression and mutational analysis of c-kit in ovarian surface epithelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Unexpected pleural effusions in 3 pediatric patients treated with STI-571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Markedly elevated levels of vascular endothelial growth factor in malignant ascites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

The microenvironment of the tumour-host interface

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Tumor microenvironment: what can effusions teach us?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Biomarker amplification by serum carrier protein binding

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22757

7 January 2021

Identifiers

DOI

10.1002/CNCR.22757

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559139%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference